How Celgene Stock Performed in 2Q17



A look at Celgene

Headquartered in Summit, New Jersey, Celgene (CELG) is one of the leading biopharmaceutical companies. It’s focused on the development of oncology drugs for the treatment of cancer as well as drugs for the treatment of inflammatory diseases.

Article continues below advertisement

Stock price performance

Celgene (CELG) stock has risen ~6.1% in 2Q17, while it has risen ~14.0% year-to-date as of July 7, 2017.

Analyst recommendations

Wall Street analysts estimate that CELG stock has the potential to rise ~8.1% over the next 12 months. Analyst recommendations show a 12-month target price of $142.67 per share compared to the last price of $131.95 on July 6, 2017.

There are 28 analysts tracking Celgene stock. Of those, 22 analysts are recommending a “buy,” five are recommending a “hold,” and one is recommending a “sell.” The consensus rating for Celgene stands at 1.9, which represents a “strong buy” for momentum investors as well as long-term growth investors.

Analysts’ revenue estimates

Celgene’s revenues are mainly driven by the strong performance of key products such as Revlimid, Pomalyst, Vidaza, and others.

Wall Street analyst estimates show revenues of $3.2 billion in 2Q17, a ~17.8% rise compared to 2Q16, and EPS (earnings per share) of $1.78 for the quarter.

To divest the company-specific risks, you can consider the iShares Global Healthcare (IXJ), which holds 2.3% of its total assets in Celgene. IXJ also holds 4.9% in Pfizer (PFE), 3.1% in Amgen (AMGN), and 4.4% in Merck & Co. (MRK).


More From Market Realist